Advertisement

Search Results

Advertisement



Your search for ,mEn matches 2738 pages

Showing 701 - 750


Prevent Cancer Foundation Awards Nine New Research Grants

The Prevent Cancer Foundation has announced funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for 2 years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone ...

Expert Point of View: Joshi J. Alumkal, MD

Invited discussant of the ACIS study, Joshi J. Alumkal, MD, leader of the Genitourinary Medical Oncology Section at the University of Michigan Rogel Cancer Center, noted that the toxicities were slightly higher with apalutamide plus abiraterone acetate/prednisone, including fatigue, hypertension,...

prostate cancer

Comparing Radiotherapy Regimens for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

A dose-intensified approach to salvage radiotherapy failed to show superiority to a conventional-dose strategy in patients with biochemically recurrent prostate cancer who had undergone radical prostatectomy, according to the phase III SAKK 09/10 trial presented at the 2021 Genitourinary Cancers...

prostate cancer

LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy reduced the risk of disease progression or death by 37% vs cabazitaxel in men with metastatic castration-resistant prostate cancer in the TheraP phase II trial reported at the 2021...

covid-19

Rates of Seroconversion Among Patients With Cancer Infected With COVID-19

Most people with cancer who are infected with COVID-19 produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on the type of malignancy and the treatments they’ve received, according to a new study published by Thakkar et al in Nature Cancer. The...

solid tumors

Analysis From the International Germ Cell Cancer Collaborative Group Update Consortium

In an analysis of a modern cohort of patients with metastatic seminoma reported in the Journal of Clinical Oncology, Beyer et al, members of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium, found that progression-free and overall survival have improved compared...

issues in oncology
prostate cancer

Patient Refusal of Provider-Recommended Locoregional Treatment for Prostate Cancer: Sociodemographic Factors

In a study reported in JCO Oncology Practice, Dee et al found that the rate of refusal of provider-recommended locoregional treatment for localized prostate adenocarcinoma has increased over time, with Black and Asian men with intermediate- or higher-risk disease being more likely to refuse such...

prostate cancer
issues in oncology

Can Treatment for Prostate Cancer Affect Smell and Taste?

One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al in the journal Supportive Care in Cancer. The study authors noted that a reduced sense of smell and taste among some patients with...

issues in oncology
gynecologic cancers
cost of care

Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?

Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...

prostate cancer

ASCO Guideline Update Offers Four Standards of Care for Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer

A recent ASCO guideline update, prompted by data from several phase III randomized controlled trials, summarizes the evidence supporting the best initial treatment options for the management of noncastrate advanced, recurrent, or metastatic prostate cancer. The hope is that the guideline will help...

hepatobiliary cancer
genomics/genetics

In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?

With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...

issues in oncology

Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis

The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...

lung cancer

USPSTF Issues Final Recommendation Statement on Screening for Lung Cancer

Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends yearly screening using a low-dose computed tomography (CT) scan for people aged...

prostate cancer

Cardiovascular Events With Transdermal Estradiol vs LHRH Agonists for Androgen Suppression in Advanced Prostate Cancer

In an analysis from the UK phase II/III PATCH trial reported in The Lancet, Langley et al found no differences in cardiovascular event rates over long-term follow-up with the use of a transdermal estradiol patch vs luteinizing hormone-releasing hormone agonists (LHRHa) for androgen suppression in...

prostate cancer

Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

In the phase II TRANSFORMER trial reported in the Journal of Clinical Oncology, Denmeade et al found no difference in progression-free survival with bipolar androgen therapy—defined as rapid cycling between high and low serum testosterone—vs enzalutamide in men with metastatic castration-resistant...

prostate cancer

LuPSMA Leads to Improved PSA Response, Fewer Severe Adverse Events Than Cabazitaxel in Patients With Metastatic Prostate Cancer

In the Australian phase II trial TheraP reported in The Lancet, Michael S. Hofman, FRACP, MBBS, and colleagues found that Lutetium-177–labeled PSMA-617 (LuPSMA) treatment was associated with a higher prostate-specific antigen (PSA) response rate and fewer severe adverse events vs cabazitaxel in...

survivorship
issues in oncology

Ongoing Surveillance and Efforts to Reduce Smoking and Obesity Needed to Lower Cancer Survivors’ Risks of New Cancers

The risk of developing or dying of a new primary cancer, particularly those cancers associated with smoking and obesity, was greater among survivors of adult-onset cancers than the expected risk in the general population, according to an analysis of data from more than 1.5 million cancer...

Conversations With the Pioneers of Oncology: Emil J Freireich, MD, FASCO

To hear an interview with Dr. Freireich by Daniel F. Hayes, MD, FASCO, of the University of Michigan Rogel Cancer Center and Past President of ASCO, visit the Journal of Clinical Oncology’s podcast, Cancer Stories, wherever you get your podcasts. In this episode, the Cancer Stories podcast reflects ...

Oncology Community Mourns the Death of Chemotherapy Pioneer Emil J Freireich, MD, FASCO

Legendary oncologist Emil J Freireich, MD, FASCO, died from COVID-19 on February 1, 2021, at The University of Texas MD Anderson Cancer Center in Houston, where he had worked for 50 years. He was 93. During a career that spanned more than 6 decades, Dr. Freireich was relentless in pursuing cures...

prostate cancer

Bone Metastatic Burden and Survival Outcomes With Prostate Radiotherapy for Newly Diagnosed Metastatic Disease

In an analysis from the STAMPEDE trial reported in JAMA Oncology, Ali et al found that a lower number of bone metastases was associated with improved overall and failure-free survival in patients receiving prostate radiotherapy for newly diagnosed M1 metastatic prostate cancer. Study Details The...

prostate cancer

MRI-Targeted Biopsy vs Systematic Transrectal Ultrasonography Biopsy for Detection of Disease in Men at Risk for Prostate Cancer

In a Canadian phase III trial reported in JAMA Oncology, Klotz et al found that multiparametric magnetic resonance imaging (MRI) with targeted biopsy was noninferior to systematic 12-core transrectal ultrasonography biopsy in detecting International Society of Urological Pathology grade group 2...

supportive care
survivorship

Telephone-Supported Depression Self-Care Intervention for Cancer Survivors

In a Canadian study reported in the Journal of Clinical Oncology, McCusker et al found that a telephone-supported depression self-care intervention called CanDirect was effective in managing mild-to-moderate depression symptoms in cancer survivors. Study Details The study involved 245 patients who...

leukemia
issues in oncology

Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML

It has been well documented that, collectively, Black individuals have the highest death rates and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have the highest cancer incidence.1 Although the causes of these inequities are complex and include...

solid tumors

Comparison of Imaging Regimens for Stage I Seminoma After Orchiectomy

Men who have had treatment for early-stage testicular cancer may benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging, according to results from the phase III TRISST clinical trial presented by Joffe et al at the...

prostate cancer

LuPSMA vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Phase II TheraP Trial

Following disease progression on docetaxel, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy reduced the risk of disease progression or death by 37% vs cabazitaxel in men with metastatic castration-resistant prostate cancer in the phase II TheraP trial reported by Michael S....

thyroid cancer

Study Links Exposure to Nighttime Artificial Lights With Possible Elevated Risk of Thyroid Cancer

People living in regions with high levels of outdoor artificial light at night may face a higher risk of developing thyroid cancer, according to a study published by Zhang et al in the journal Cancer. Link Between Nighttime Light and Cancer Risk Over the past century, nightscapes—especially in...

breast cancer

Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?

A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...

Enrollment Up at U.S. Medical Schools

The number of first-year students in U.S. medical schools increased by 1.7% in the 2020 academic year, according to data released recently by the Association of American Medical Colleges (AAMC). Although the increase was modest, the number of students applying to medical school for the upcoming...

prostate cancer

Increase in Metastatic Prostate Cancer Diagnoses in the United States After Reduction in PSA Screening

Reduced levels of screening for prostate cancer using prostate-specific antigen (PSA) testing correspond with recent increases in the diagnosis of metastatic disease in the United States, according to a study that will be presented by Vidit Sharma, MD, and colleagues at the 2021 Genitourinary...

Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79

Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature.  “At St. Jude, the nature of our work requires a bold, ambitious...

covid-19

HERO-TOGETHER: Opportunity for Health-Care Workers to Share Their Experience With COVID-19 Vaccination

HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people fare after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health-care providers everywhere have worked together to face. On the...

colorectal cancer

Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk

At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...

colorectal cancer

Study Shows Aspirin Use Before Diagnosis May Lower Colorectal Cancer Mortality

A recent study found that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower colorectal cancer–specific mortality. The report, published by Figueiredo et al in JNCI: The Journal of the National Cancer Institute, suggests that the findings for prediagnosis...

lung cancer
issues in oncology

Featured Presentations at WCLC Focus on Disparities in Patients With Lung Cancer

At a press briefing held by the International Association for the Study of Lung Cancer (IASLC), researchers presented new data that revealed factors relating to race, gender, sexual orientation, and income continue to be significant barriers to those living with lung cancer. The press briefing is...

prostate cancer

Shorter Radiation Course for Men With Advanced Prostate Cancer: Safety and Efficacy

A study led by researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center found that shortening a traditional 45-day course of radiation to a 5-day course delivered in larger doses was safe and as effective as conventional radiation for men with high-risk...

breast cancer

Adding Entinostat to Exemestane Fails to Overcome Aromatase Inhibitor Resistance in Advanced Breast Cancer

The histone deacetylase inhibitor (HDAC) entinostat, added to exemestane, failed to overcome endocrine therapy resistance in advanced breast cancer, according to the E2112 phase III trial conducted by the ECOG-ACRIN Cancer Research Group. Results showed that overall survival was not improved by the ...

prostate cancer

Relugolix for Advanced Prostate Cancer

On December 18, 2020, relugolix was approved for the treatment of adult patients with advanced prostate cancer. Relugolix is the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist to be approved in this setting.1,2 Supporting Efficacy Data Approval was based on findings in the...

issues in oncology

New Report Shows Alcohol Consumption Is Linked to Cancer Incidence and Mortality in All 50 States

A new study has found that alcohol consumption accounts for a considerable portion of cancer incidence and mortality in all 50 states and the District of Columbia. The article, published by Sauer et al in Cancer Epidemiology, stated that the proportion of cancer cases attributable to alcohol...

breast cancer
issues in oncology

Performing Mammograms for Targeted Hospitalized Patients

Completing cancer screening tests such as mammograms can be challenging for low-income patients who may face such issues as lack of transportation or inability to take time off work. A team at Massachusetts General Hospital explored the possibility of addressing preventive care needs when patients...

prostate cancer

Variation in Active Surveillance for Low-Risk Prostate Cancer in the United States

In a cohort study reported in JAMA Network Open, Washington et al found that the use of active surveillance or watchful waiting for patients with low-risk prostate cancer in the United States varied by region, but not according to factors such as Black race or county-level socioeconomic status. As...

issues in oncology
lung cancer
gynecologic cancers

Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’

Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...

lung cancer
prostate cancer
immunotherapy
genomics/genetics

FDA Pipeline: Two Reviews in NSCLC, Plus Prescribing Information Update for Darolutamide

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to lorlatinib in ALK-positive non–small cell lung cancer (NSCLC) and Breakthrough Therapy designation to the combination of tiragolumab plus atezolizumab in NSCLC with high PD-L1 expression. The FDA also updated the...

prostate cancer

Does Following a Mediterranean Diet Reduce the Risk of Disease Progression in Men on Active Surveillance for Prostate Cancer?

In a study examining the effect of a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style...

prostate cancer
symptom management

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer

Many patients with prostate cancer are treated with androgen-deprivation therapy. However, patients receiving androgen-deprivation therapy often experience higher levels of fatigue, depression, and cognitive impairment. In a new study published by Hoogland et al in the journal Cancer, researchers...

prostate cancer
genomics/genetics

Multiancestry Meta-analysis of Prostate Cancer Genetics

A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever...

survivorship

Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy?

A study published by Hyuna Sung, PhD, and colleagues in JAMA found that adult-onset cancer survivors may have a greater risk of developing and dying from subsequent primary cancers than the general population. Cancers associated with smoking or obesity accounted for a majority of subsequent primary ...

global cancer care

GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths

On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...

issues in oncology

Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients

Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...

Rutgers Researcher Receives $400K Grant to Examine Racial Health Disparities in Cancer Care

Anita Kinney, PhD, MSN, Professor at the Rutgers School of Public Health and Associate Director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is among 10 recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to...

issues in oncology
global cancer care

European Experts Tackle HPV-Related Cancers

The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...

Advertisement

Advertisement




Advertisement